The calendar
Every upcoming readout, decision and trial completion we track, drawn from ClinicalTrials.gov. Only companies whose ticker we could verify against SEC's register appear here, because a wrong ticker is worse than a missing one.
Loading catalysts…
153 catalysts · 39 companies
| Ticker | Catalyst | Phase | Expected |
|---|---|---|---|
| PFE | Phase 3 primary completion: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Pfizer · Multiple Myeloma | P3 | 2026-08-30in 14 days |
| MSLE | Phase 2 primary completion: An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy (DMD) | P2 | 2026-08-30in 14 days |
| VSTM | Phase 2 primary completion: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerVerastem, Inc. · KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas | P2 |
| 2026-08-31in 15 days |
| PFE | Phase 3 primary completion: A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.Pfizer · Respiratory Syncytial Virus (RSV) | P3 | 2026-08-31in 15 days |
| DSGN | Phase 2 primary completion: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyDesign Therapeutics, Inc. · Fuchs Endothelial Corneal Dystrophy, Fuchs | P2 | 2026-09-01in 16 days |
| CORT | Phase 2 primary completion: Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesCorcept Therapeutics · Neoplasms | P2 | 2026-09-01in 16 days |
| TLSA | Phase 2 primary completion: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsTiziana Life Sciences LTD · Secondary Progressive Multiple Sclerosis | P2 | 2026-09-01in 16 days |
| VNDA | Phase 2 primary completion: An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeVanda Pharmaceuticals · Dry Eye | P2 | 2026-09-01in 16 days |
| NVO | Phase 2 primary completion: A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNovo Nordisk A/S · Chronic Kidney Disease | P2 | 2026-09-01in 16 days |
| ABBV | Phase 3 primary completion: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabAbbVie · Juvenile Psoriatic Arthritis | P3 | 2026-09-01in 16 days |
| GILD | Phase 2 primary completion: Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionGilead Sciences · Chronic Hepatitis B | P2 | 2026-09-01in 16 days |
| ARDX | Phase 3 primary completion: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsArdelyx · Irritable Bowel Syndrome With Constipation (IBS-C) | P3 | 2026-09-01in 16 days |
| SUPN | Phase 3 primary completion: Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Supernus Pharmaceuticals, Inc. · Attention-Deficit/Hyperactivity Disorder | P3 | 2026-09-01in 16 days |
| LLY | Phase 2 primary completion: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesEli Lilly and Company · Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D | P2 | 2026-09-01in 16 days |
| IRON | Phase 3 primary completion: Study of Bitopertin in Participants With EPP or XLP (APOLLO)Disc Medicine, Inc · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | P3 | 2026-09-01in 16 days |
| CYTK | Phase 2 primary completion: AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFCytokinetics · Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | P2 | 2026-09-01in 16 days |
| VNDA | Phase 2 primary completion: Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisVanda Pharmaceuticals · Onychomycosis of Toenail | P2 | 2026-09-01in 16 days |
| EWTX | Phase 2 primary completion: Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy | P2 | 2026-09-01in 16 days |
| CL | Phase 3 primary completion: Comparative Efficacy of Different Dentin Occluding Toothpaste TechnologiesColgate Palmolive · Dentinal Sensitivity, Dentinal Hypersensitivity | P3 | 2026-09-01in 16 days |
| CORT | Phase 2 primary completion: A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Corcept Therapeutics · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | P2 | 2026-09-01in 16 days |
| LLY | Phase 3 primary completion: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Eli Lilly and Company · Perennial Allergic Rhinitis (PAR) | P3 | 2026-09-01in 16 days |
| AVIR | Phase 3 primary completion: C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVAtea Pharmaceuticals, Inc. · HEPATITIS C VIRUS CHRONIC INFECTION | P3 | 2026-09-01in 16 days |
| VNDA | Phase 3 primary completion: Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Vanda Pharmaceuticals · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders | P3 | 2026-09-01in 16 days |
| GILD | Phase 2 primary completion: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Gilead Sciences · Non-small Cell Lung Cancer | P2 | 2026-09-01in 16 days |
| MAZE | Phase 2 primary completion: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseMaze Therapeutics · Proteinuric Kidney Disease | P2 | 2026-09-01in 16 days |
| SNDX | Phase 2 primary completion: MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Syndax Pharmaceuticals · Idiopathic Pulmonary Fibrosis | P2 | 2026-09-01in 16 days |
| VERA | Phase 2 primary completion: Monthly Dosing of Atacicept in IgANVera Therapeutics, Inc. · IgA Nephropathy (IgAN), Berger Disease | P2 | 2026-09-01in 16 days |
| SLN | Phase 2 primary completion: Study to Assess SLN124 in Patients With Polycythemia VeraSilence Therapeutics plc · Polycythemia Vera | P2 | 2026-09-01in 16 days |
| WVE | Phase 2 primary completion: A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATDWave Life Sciences USA, Inc. · Alpha-1 Antitrypsin Deficiency | P2 | 2026-09-01in 16 days |
| PCSA | Phase 2 primary completion: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerProcessa Pharmaceuticals · Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer | P2 | 2026-09-01in 16 days |
| RGNX | Phase 3 primary completion: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)REGENXBIO Inc. · Duchenne Muscular Dystrophy | P3 | 2026-09-01in 16 days |
| KPTI | Phase 2 primary completion: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisKaryopharm Therapeutics Inc · Myelofibrosis | P2 | 2026-09-01in 16 days |
| ORIC | Phase 2 primary completion: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationORIC Pharmaceuticals · Solid Tumors | P2 | 2026-09-01in 16 days |
| TNGX | Phase 2 primary completion: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsTango Therapeutics, Inc. · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma | P2 | 2026-09-01in 16 days |
| PFE | Phase 2 primary completion: A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionPfizer · Pulmonary Arterial Hypertension | P2 | 2026-09-02in 17 days |
| SNY | Phase 2 primary completion: Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSanofi · Systemic Lupus Erythematosus | P2 | 2026-09-03in 18 days |
| BMY | Phase 2 primary completion: A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsBristol-Myers Squibb · Advanced Solid Tumors | P2 | 2026-09-05in 20 days |
| IVBXF | Phase 3 primary completion: IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaInnovent Biologics (Suzhou) Co. Ltd. · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | P3 | 2026-09-06in 21 days |
| PFE | Phase 2 primary completion: A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesPfizer · Obesity and Obesity-related Medical Conditions | P2 | 2026-09-15in 30 days |
| VRTX | Phase 3 primary completion: An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantVertex Pharmaceuticals Incorporated · Type 1 Diabetes, Kidney Transplant | P3 | 2026-09-17in 1 months |
| TAK | Phase 2 primary completion: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseTakeda · Crohn's Disease | P2 | 2026-09-18in 1 months |
| CRDL | Phase 3 primary completion: CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Cardiol Therapeutics Inc. · Recurrent Pericarditis | P3 | 2026-09-21in 1 months |
| ONC | Phase 2 primary completion: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaBeOne Medicines · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | P2 | 2026-09-22in 1 months |
| PFE | Phase 2 primary completion: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPfizer · Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung | P2 | 2026-09-23in 1 months |
| IVBXF | Phase 2 primary completion: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityInnovent Biologics (Suzhou) Co. Ltd. · Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction | P2 | 2026-09-24in 1 months |
| BIIB | Phase 3 primary completion: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusBiogen · Lupus Erythematosus, Systemic | P3 | 2026-09-27in 1 months |
| AZN | Phase 2 primary completion: A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer | P2 | 2026-09-28in 1 months |
| OCGN | Phase 3 primary completion: A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseOcugen · Stargardt Disease | P3 | 2026-09-28in 1 months |
| MLTX | Phase 3 primary completion: An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa | P3 | 2026-09-28in 1 months |